Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity
- 1 October 1979
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 98 (4) , 526-535
- https://doi.org/10.1016/0002-8703(79)90261-8
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoreceptor blockerAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Comparative clinical experience and new therapeutic applicationsAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effectsAmerican Heart Journal, 1979
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic propertiesAmerican Heart Journal, 1979
- Reversal of Abnormal Platelet Aggregability and Change in Exercise Tolerance in Patients with Angina Pectoris Following Oral PropranololCirculation, 1974
- Comparison of Adrenergic Beta-receptor Antagonists in Angina PectorisBMJ, 1973
- Comparative chronotropic activity of β‐adrenoceptive antagonistsBritish Journal of Pharmacology, 1970
- Cardiovascular Pharmacology of Propranolol in ManCirculation, 1969
- Relation of Heart Rate and Systolic Blood Pressure to the Onset of Pain in Angina PectorisCirculation, 1967
- Hemodynamic changes after beta adrenergic blockadeThe American Journal of Cardiology, 1966